These results indicate that Mcl-1 has an inhibitory effect on calcium release from the ER, and that strongly decreased Mcl-1 protein levels in melanoma cells after treatment with 9.2.27PE (Fig. 4A) might be responsible for enhanced [Ca2+]i levels in ABT-737 treated cells. Here, MCL1 is linked to melanoma.